Optimization of velocity receptor transduction in CAR T cells

Xinyun Jiang1, Vasco Queiroga1,2, Eban A Hanna1,2

  • 1Institute for Nanobiotechnology, The Johns Hopkins University, Baltimore, 21218, Maryland, USA.

Insights

Synthetic cytokine receptors called velocity receptors (VRs) enhance chimeric antigen receptor (CAR) T cell migration into solid tumors. Optimizing VR transduction improves CAR T cell therapy effectiveness for difficult-to-treat cancers.

Area of Science:

  • Immunology
  • Cellular Therapy
  • Biotechnology

Background:

  • Solid tumors present a significant challenge for chimeric antigen receptor (CAR) T cell therapy due to limited infiltration.
  • Synthetic cytokine receptors, termed velocity receptors (VRs), have been developed to enhance CAR T cell motility by sensing inflammatory cytokines.
  • These VR-modified CAR T cells can achieve a self-propelled, migratory state, improving penetration into dense tumor cores.

Purpose of the Study:

  • To systematically evaluate factors influencing velocity receptor (VR) transduction for stable integration and expression.
  • To optimize the development and functional studies of VR-CAR T cells for solid tumor cellular therapies.

Main Methods:

  • Development of a dual-fluorescence reporter system for simultaneous monitoring of VR and CAR constructs.
  • Evaluation of vector construct modifications and generation of standardized infectious unit (IFU) curves.
  • Systematic assessment of lentiviral vector size reduction and its impact on transduction efficiency.

Main Results:

  • Eliminating non-coding sections (cPPT) of lentiviral vectors did not improve transduction efficiency.
  • A log-linear relationship was observed between viral dose and transduction efficiency for specific VRs.
  • VR5αIL8 and VR5αTNFα demonstrated superior performance compared to VR5αIL5 and the native IL5 receptor (V5).

Conclusions:

  • An optimized and reproducible framework for VR transduction has been established.
  • These findings provide guidance for the future development of VR-CAR T cells.
  • Enhanced CAR T cell migration is crucial for improving solid tumor treatment efficacy.